AB0059 Fetuin-a: clinical and laboratory associations in women with rheumatoid arthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Papichev, E.; Sivordova, L.; Polyakova, J.; Akhverdyan, Y.; Zavodovsky, B.; Rogatkina, T.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1228
• Page End: 1228
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.2111
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Fetuin-A is an acute-phase protein with contradictory effects. It is well kno wn that fetuin-A low levels are associated with calcification and higher risk of cardiovascular diseases and its level is downregulated by pro-inflammatory cytokines. 1 Nevertheles, it was shown, that fetuin-A induces synthesis of pro-inflammatory cytokines in adipocites and macrophages. 2 Objectives: To investigate the level of fetuin-A in women with rheumatoid arthritis (RA). Methods: At baseline we measured fetuin-A level, femoral neck, total hip and LI -LIV BMD by DXA in 110 women with RA (mean age 54, 5±12, 6; hereinafter M±Std.dev.) and 30 healthy controls. Serum CRP and ESR were measured to assess inflammation. DAS28 was calculated to determine RA activity. The diagnosis of osteoporosis was set according to the recommendations of world health organisation – T-score≤−2, 5 for patients without glucocorticoid therapy in anamnesis, T-score≤−1, 5 for patients treated with glucocorticoid for 3 months in anamnesis or with an osteoporotic fracture in anamnesis. Fetuin-A in serum was determined by enzyme-linked immunosorbent assay. Results: Mean concentration of fetuin-A in group with RA was 765, 69±120, 64 ug/ml, which was lower than of healthy controls – 812, 95 ug/ml (p=0, 0438). Secondary osteoporosis was revealed in 52 patients (47%) with RA with mean level of fetuin-A at 733, 7±18, 83 ug/ml vs. 794, 36±12, 83 ug/ml (p=0, 0078) of 58 (53%) non-osteoporotic patients. Moderate negative correlations were observed between fetuin-A and DAS28 (r=-0, 4334; p<0, 001), fetuin-A and CRP (r=-0, 3148; p<0, 001), fetuin-A and ESR (p=-0, 344; p<0, 001). Mean concentrations of fetuin-A were significantly different between the subgroups with moderate (3, 2≤DAS28<5, 1) and high disease activity (5, 1≤DAS28) of RA patients and healthy controls: 742, 41±12, 07 ug/ml vs. 812, 95 ug/ml (p=0, 0021) and 663, 9±39, 14 ug/ml vs. 812, 95 ug/ml (p<0, 001). Conclusions: Our study confirm s that lower levels of fetuin- A are associated with higher activity of RA and with the loss of bone mineral density. References: [1] Brylka L, et al. Calcif Tissue Int2012;93(4):355–364. [2] Stefan N, et al. Diabetes2008;57(10):2762–2767. Disclosure of Interest: None declared